Bokf Na cut its holdings in Edwards Lifesciences Co. (NYSE:EW – Free Report) by 10.2% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 42,532 shares of the medical research company’s stock after selling 4,809 shares during the period. Bokf Na’s holdings in Edwards Lifesciences were worth $3,519,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also modified their holdings of EW. Core Alternative Capital boosted its holdings in shares of Edwards Lifesciences by 96.1% in the 1st quarter. Core Alternative Capital now owns 353 shares of the medical research company’s stock valued at $29,000 after buying an additional 173 shares during the period. Addison Advisors LLC boosted its stake in Edwards Lifesciences by 708.0% during the 4th quarter. Addison Advisors LLC now owns 404 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 354 shares during the period. Compass Wealth Management LLC acquired a new position in Edwards Lifesciences during the 4th quarter valued at about $31,000. Jones Financial Companies Lllp acquired a new position in Edwards Lifesciences during the 1st quarter valued at about $33,000. Finally, MCF Advisors LLC boosted its stake in Edwards Lifesciences by 179.6% during the 1st quarter. MCF Advisors LLC now owns 411 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 264 shares during the period. 79.25% of the stock is owned by institutional investors and hedge funds.
In other news, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction that occurred on Friday, June 30th. The shares were sold at an average price of $93.27, for a total transaction of $676,673.85. Following the sale, the chief financial officer now owns 19,248 shares in the company, valued at $1,795,260.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Michael A. Mussallem sold 29,350 shares of the business’s stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $84.46, for a total transaction of $2,478,901.00. Following the transaction, the director now directly owns 86,210 shares of the company’s stock, valued at $7,281,296.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction that occurred on Friday, June 30th. The shares were sold at an average price of $93.27, for a total transaction of $676,673.85. Following the transaction, the chief financial officer now directly owns 19,248 shares in the company, valued at $1,795,260.96. The disclosure for this sale can be found here. Insiders have sold 152,604 shares of company stock worth $13,088,354 over the last 90 days. 1.29% of the stock is owned by company insiders.
Analysts Set New Price Targets
Edwards Lifesciences Stock Down 0.2 %
NYSE EW opened at $76.03 on Tuesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.15 and a quick ratio of 2.30. The company’s 50 day simple moving average is $85.76 and its 200 day simple moving average is $84.18. Edwards Lifesciences Co. has a 12 month low of $67.13 and a 12 month high of $98.35. The company has a market capitalization of $46.22 billion, a P/E ratio of 33.64, a PEG ratio of 4.11 and a beta of 1.02.
Edwards Lifesciences (NYSE:EW – Get Free Report) last released its quarterly earnings results on Wednesday, July 26th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.01. Edwards Lifesciences had a net margin of 24.56% and a return on equity of 25.43%. The business had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.51 billion. During the same quarter in the previous year, the business earned $0.63 earnings per share. The firm’s revenue was up 11.4% compared to the same quarter last year. Equities research analysts expect that Edwards Lifesciences Co. will post 2.55 earnings per share for the current fiscal year.
Edwards Lifesciences Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.
- Five stocks we like better than Edwards Lifesciences
- What is the FTSE 100 index?
- 3 Winning Retail Stocks Income Investors Can Rely On
- What Are Dividends? Buy the Best Dividend Stocks
- PayPal Is Your Chance To Prove You’re A True Value Investor
- How Technical Indicators Can Help You Find Oversold Stocks
- Target’s Undervalued Moat: A Story Of Industry Favoritism
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.